Reagentes e instrumentos para imunologia, biologia celular e biologia molecular.

Fructose [7660-25-5]

Imprimir

Referência NB-64-18487-1g

Tamanho : 1g

Contactar o distribuidor local :

Telefone : +1 850 650 7790

Solicitar mais informações

Contactar o distribuidor local :

Telefone : +1 850 650 7790

Remove All

Fructose

(Synonyms: Fructopyranose) Copy Product Info

Synonyms: Fructopyranose

Catalog No. T2954 Copy Product Info

Purity: 99.83%

Fructose is a simple ketose monosaccharide widely found in many plants and commonly combines with glucose to form the disaccharide sucrose. It can be used to induce hyperuricemia and diabetes models.

Cas No. 7660-25-5

For research use only—not for human use. No sales to individuals. Use as intended only.

Select Batch

Purity:99.83%

Color:White

Product Introduction

Bioactivity

Description	Fructose is a simple ketose monosaccharide widely found in many plants and commonly combines with glucose to form the disaccharide sucrose. It can be used to induce hyperuricemia and diabetes models.
Synonyms	Fructopyranose
Disease Modeling Protocol	Hyperuricemia model Modeling Mechanism： ① Fructose consumes ATP during liver metabolism, stimulates purine degradation to produce uric acid, and reduces uric acid excretion; ② Potassium oxalate inhibits uricase activity, blocks uric acid decomposition, and synergistically increases serum uric acid (UA) with fructose; ③ Long-term high fructose intake further induces insulin resistance, dyslipidemia, and liver and kidney damage, mimicking the pathological features of hyperuricemia combined with metabolic syndrome. Related Products： Fructose (T2954) Modeling Method： Experimental Subject： Rats, Wistar, Male, 7–8 weeks old, Body weight 200–220 g Dosage and Administration Route： Control group: Equivalent volume saline solution, Intraperitoneal injection (i.p.). Hyperuricaemia model group: Potassium oxalate 250 mg/kg, dissolved in physiological saline, intraperitoneal injection (i.p.). Hyperuricaemia+Fructose group: ① Potassium oxalate 250 mg/kg dissolved in physiological saline, administered intraperitoneally (i.p.); ② One hour later: Fructose 8 mg/kg dissolved in distilled water, administered via gastric lavage. Hyperuricaemia+L-carnitine intervention group: ① Potassium oxalate 250 mg/kg, dissolved in physiological saline, administered via intraperitoneal injection (i.p.); ② Two hours later: L-carnitine 500 mg/kg, administered via intraperitoneal injection (i.p.). Hyperuricaemia+Fructose+L-carnitine intervention group: ① Potassium oxalate 250 mg/kg, dissolved in physiological saline, intraperitoneal injection (i.p.);② One hour later: Fructose 8 mg/kg, dissolved in distilled water, oral gavage; ③ A further hour later: L-carnitine 500 mg/kg, intraperitoneal injection (i.p.). Dosing Frequency and Duration Model： Once daily for 4 consecutive weeks Validation： 1. Biochemical indicators: - Serum UA was significantly elevated (p<0.001), and higher than that of the potassium oxalate model group alone; - Fasting blood glucose (FBG) and HOMA-IR (insulin resistance index) were significantly elevated (p<0.001); - Serum total cholesterol and triglycerides were elevated (p<0.001), and albumin was decreased (p<0.001); - Plasma MDA (malondialdehyde) was elevated, and TAC (total antioxidant capacity) was decreased (p<0.001); 2. Pathological indicators: - Liver: vacuolar degeneration of hepatocytes, fatty infiltration, inflammatory cell infiltration in the portal vein area, and necrosis in some areas; - Kidneys: glomerular atrophy, enlargement of Bowman's capsule, vacuolar degeneration of renal tubular epithelial cells, and hyaline cast formation; 3. Metabolic phenotype: BMI and waist circumference were significantly increased (p<0.05), showing characteristics of abdominal obesity. Precautions： The animals were euthanized after the experiment. References：El-Kafoury BMA,et,al. Possible role of l-carnitine in improvement of metabolic and hepatic changes in hyperuricemic and hyperuricemic-Fructose-supplemented rats. Physiol Rep. 2019 Nov;7(22):e14282.

Chemical Properties

Molecular Weight	180.16
Formula	C₆H₁₂O₆
Cas No.	7660-25-5
Smiles	OC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O
Relative Density.	1.758 g/cm3

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 242.5 mg/mL (1346.03 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (11.1 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	5.5506 mL	27.7531 mL	55.5062 mL	277.5311 mL
5 mM	1.1101 mL	5.5506 mL	11.1012 mL	55.5062 mL
10 mM	0.5551 mL	2.7753 mL	5.5506 mL	27.7531 mL
20 mM	0.2775 mL	1.3877 mL	2.7753 mL	13.8766 mL
50 mM	0.1110 mL	0.5551 mL	1.1101 mL	5.5506 mL
100 mM	0.0555 mL	0.2775 mL	0.5551 mL	2.7753 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 µL Tween 80 and mix well until fully clarified.

3) Add 450 µL Saline,PBS or ddH₂O and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

Keywords

InhibitorinhibitFructose

Related Tags: Fructose chemical structure | Fructose formula | Fructose molecular weight